Recommended Next-Line Regimen After Non-Bismuth, Non-Rifabutin H. pylori Treatment Failure
After failure of a non-bismuth, non-rifabutin H. pylori regimen (typically clarithromycin-based triple therapy or concomitant therapy), bismuth quadruple therapy for 14 days is the preferred next-line treatment, achieving eradication rates of 76.7-90.8%. 1, 2
Primary Recommendation: Bismuth Quadruple Therapy (14 days)
The standard regimen consists of:
- Bismuth subsalicylate 300 mg four times daily
- Tetracycline 500 mg four times daily
- Metronidazole 500 mg four times daily
- PPI (standard dose) twice daily 1
This achieves mean eradication rates of 69.2-90.8% in intention-to-treat analysis across multiple studies 1, 3. The 2024 ACG guideline specifically endorses this as preferred empiric therapy when antibiotic susceptibility is unknown 2.
Alternative Option: Rifabutin Triple Therapy (14 days)
If bismuth quadruple therapy has already been used or is unavailable:
- Rifabutin 150 mg twice daily
- Amoxicillin 1 g three times daily
- High-dose PPI (esomeprazole or rabeprazole 40 mg) twice daily 1, 4
This achieves eradication rates of 75.4-81.6% as rescue therapy 3. The 2021 AGA guideline notes that rifabutin resistance is rare (<1%), making this reasonable for empiric use 1, 4.
Important caveat: Rifabutin can cause reversible myelotoxicity (leukopenia, thrombocytopenia), requiring monitoring 5. Recent 2026 data shows adding bismuth to rifabutin triple therapy significantly improves eradication (80% vs 60.4%, p=0.030), though with more mild adverse events 6.
Critical Decision Points
When to Avoid Levofloxacin-Based Therapy
Do NOT use levofloxacin triple therapy empirically—it achieves only 55.7-60.6% eradication rates as rescue therapy 3. Levofloxacin should only be used with confirmed susceptibility testing 1.
When to Pursue Susceptibility Testing
After two failed therapies with confirmed patient adherence, susceptibility testing should be obtained to guide subsequent regimens 1. This is particularly important before considering third-line or later attempts.
Penicillin Allergy Considerations
If true penicillin allergy exists after first-line failure, bismuth quadruple therapy remains the optimal choice since it contains tetracycline and metronidazole rather than amoxicillin 1.
Common Pitfalls to Avoid
Insufficient duration: Always use 14-day regimens, not 7-10 days, for rescue therapy 1, 2
Inadequate PPI dosing: Use standard-dose PPI twice daily (minimum omeprazole 40 mg equivalent) taken 30 minutes before meals 1
Metronidazole resistance: While metronidazole resistance rates reach 96% in some populations 7, bismuth quadruple therapy remains effective because bismuth has synergistic bacteriostatic effects that overcome resistance 6
Compliance issues: Bismuth quadruple therapy requires taking medications four times daily. The combination product Pylera® simplifies this but costs >$1,000 in the US (vs ~€70 in Europe); generic components with GoodRx coupons can reduce costs to <$100 4
Regimens to Avoid
Do not use concomitant, hybrid, reverse hybrid, or sequential therapies as rescue treatment—these are considered obsolete and include antibiotics that provide no therapeutic benefit while increasing antimicrobial resistance 4.
Emerging Options
Vonoprazan-amoxicillin dual therapy showed only 75.8% eradication as rescue treatment in a 2026 trial and was non-inferior to bismuth quadruple therapy, making it unsuitable for empiric rescue use 7. Vonoprazan-rifabutin-amoxicillin achieved 90% eradication but is not yet widely available 7.